UROTHELIAL CANCER

This large, late-stage trial is testing whether two immunotherapy drugs, given alone or together, can help people with advanced bladder cancer live longer than standard chemotherapy. The study enrolled over 1,100 patients who had not yet received treatment for their cancer that h…

This study tested a targeted drug called erdafitinib in people with advanced bladder cancer that has spread or cannot be removed by surgery and has specific genetic changes (FGFR alterations). The main goal was to see how well the drug shrinks tumors and controls the cancer. Rese…

This early-stage trial is testing the safety of a new treatment called ADP-A2M4CD8, which uses a patient's own modified immune cells to fight cancer. The study will enroll 120 adults with one of nine advanced cancers who have specific genetic markers. Researchers will give the ce…

This was an early safety study for people with advanced bladder cancer that had spread. It aimed to test a combination of three drugs to see if they could control the cancer and were safe to use together. The study was withdrawn before any participants were enrolled.

This early-stage study is testing a new drug called BT5528 in people with advanced solid tumors that have spread or returned. The main goals are to find a safe dose, understand the side effects, and see if the drug shows early signs of helping to control cancers like ovarian, lun…

This study is testing an experimental drug called enfortumab vedotin, both by itself and combined with other cancer therapies, for people with advanced bladder and urinary tract cancers. It aims to find safe doses and see if these treatments can shrink tumors. The study includes …

This early-stage trial is testing the safety and finding the right dose of a two-drug combination (naptumomab estafenatox and durvalumab) for people with advanced or metastatic solid tumors. It will enroll about 120 adults with one of many eligible cancer types, including breast,…

This study is testing whether a two-drug immunotherapy treatment can help keep advanced bladder cancer from getting worse in patients who initially benefited from chemotherapy. It will involve about 66 adults whose cancer has not progressed after their first round of chemo. The g…

This study is testing two new immunotherapy drugs, alone and together, against an existing drug for advanced bladder cancer. It is for patients whose cancer has spread and who are not healthy enough for standard platinum-based chemotherapy. The main goal is to see if the new trea…

This study is testing whether a targeted drug called erdafitinib works better than standard chemotherapy or immunotherapy for people with advanced bladder cancer that has specific genetic changes. It involves about 629 adults whose cancer has worsened after one or two prior treat…

This large, late-stage study is comparing new immunotherapy drug combinations against standard chemotherapy for people with advanced bladder cancer that has spread or cannot be removed by surgery. It enrolled over 1,300 patients who had not received prior treatment for their adva…

This study is creating a large registry to learn more about urinary tract cancers like bladder cancer. Researchers are collecting health information and saliva samples from over 3,500 people, including those with cancer and those without, to look for genetic markers and other ris…